Alimera Sciences Inc. (ALIM)

0.84
NASDAQ : Health Technology
Prev Close 0.84
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.72 / 1.34
Avg Volume 87.30K
Exchange NASDAQ
Shares Outstanding 70.08M
Market Cap 59.57M
EPS -0.30
P/E Ratio 5.67
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Announces Nine Clinical Presentations And A Sponsored Symposium At 18th EURETINA Congress

Alimera Sciences Announces Nine Clinical Presentations And A Sponsored Symposium At 18th EURETINA Congress

"CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the Treatment of Persistent or Recurrent DME" Symposium to be held on Friday

Alimera Sciences Announces Three Podium Presentations For ILUVIEN® To Be Presented At 2018 Retina Society's Annual Meeting

Alimera Sciences Announces Three Podium Presentations For ILUVIEN® To Be Presented At 2018 Retina Society's Annual Meeting

ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc.

Alimera Sciences Announces Exchange Of Series B Preferred Stock For Newly Issued Series C Preferred Stock

Alimera Sciences Announces Exchange Of Series B Preferred Stock For Newly Issued Series C Preferred Stock

ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc.

Alimera Sciences To Present At The 20th Annual HC Wainwright Global Investment Conference

Alimera Sciences To Present At The 20th Annual HC Wainwright Global Investment Conference

ATLANTA, Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive...

Alimera Sciences To Present At The Annual B. Riley Healthcare Conference

Alimera Sciences To Present At The Annual B. Riley Healthcare Conference

ATLANTA, Aug. 28, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive...

Alimera Sciences Reports Second Quarter 2018 Results

Alimera Sciences Reports Second Quarter 2018 Results

- Record Net Revenue of $10.9 Million in Q2 2018

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

TheStreet Quant Rating: D (Sell)